XSTO
KDV B
Market cap7mUSD
Sep 17, Last price
0.27SEK
1D
-1.80%
1Q
-1.97%
Jan 2017
-95.45%
IPO
-99.31%
Name
Karolinska Development AB
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Karolinska Development AB (publ) operates as a venture capital firm, primarily focused on providing funding to nascent companies across seed, early, and growth stages. Its investment strategy targets a wide array of life science domains, including pharmaceutical and genetic research and development, medical advancements, healthcare technology, innovative drug delivery systems, biotechnology, and specialized tools and service providers for the life science industry. The company strategically prioritizes investment opportunities within the Nordic region, specifically highlighting Sweden, Iceland, Norway, Finland, and Denmark. While the firm prefers to assume the role of a lead investor in its portfolio enterprises, it also remains open to participating in co-investment ventures. On an annual basis, it endeavors to finance a maximum of five new projects. Karolinska Development AB (publ) was established in 2003 and maintains its headquarters in Stockholm, Sweden.
Related entities
Subsidiaries
KDev Investments AB
Key people
Esther Miralles Simo
Analyst · since 2018
Director · since 2014
Independent Director · since 2017
Theresa Tse
Independent Director · since 2017
Independent Chairman of the Board · since 2017
IPO date
Apr 15, 2011
Employees
8
Domiciled in
SE
Incorporated in
SE
Headquarters & legal address
Nanna Svartz väg 6A
Solna, AB 171 65
SE
Solna, AB 171 65
SE
Address
Nanna Svartz vag 6A
Solna, AB 171 65
SE
Solna, AB 171 65
SE
Previous name
Karolinska Development AB
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||